Outcomes of 38 patients with PFIC3: Impact of genotype and of response to ursodeoxycholic acid therapy.

Background & Aims: Progressive familial intrahepatic cholestasis type 3 (PFIC3) is a rare liver disease caused by biallelic variations in . Data reporting on the impact of genotype and of response to ursodeoxycholic acid (UDCA) therapy on long-term outcomes are scarce.

Methods: We retrospectively describe a cohort of 38 patients with PFIC3 with a median age at last follow-up of 19.

Beam propagation constants for a radial laser array.

The beam quality of a radial laser array, quantified in terms of the M(2) propagation constant, is determined as a function of array element configuration. A lower bound on array M(2) is estimated for both phase-locked and nonphase-locked conditions. It is shown that, to achieve near-unity M(2) array, either aperture filling or spatial filtering is required in addition to phase locking.

Synthesis, characterization and comparative biodistribution study of a new series of p-iodine-125 benzamides as potential melanoma imaging agents.

Iodobenzamides are reported to possess some affinity for melanoma. In order to identify the compound having the most appropriate pharmacokinetic properties as a potential melanoma imaging agent, thirteen new [125I]radioiodobenzamides with a butylene amide-amine spacer and various substituents on the terminal amino group were investigated. Their synthesis, radioiodination and biodistribution in B16 melanoma bearing C57BL6 mice are described and compared to [125I] labeled N-(2-diethylaminoethyl)-4-iodobenzamide ([125I]BZA), our reference compound.

Optical performance of a burst-mode multikilowatt CO(2) laser.

A unique advancement in the flexibility of high-power lasers is presented. Operation of a 20-kW, continuous-wave, CO(2) laser with a burst excitation technique produces a broad range of optical output characteristics. A detailed discussion of the discharge excitation of this system demonstrates some unique features of the process.

Synthesis, radiolabeling, and preliminary evaluation in mice of some (N-diethylaminoethyl)-4-iodobenzamide derivatives as melanoma imaging agents.

N-(2-Diethylaminoethyl)-4-iodobenzamide (BZA) is a radiopharmaceutical recently developed in our laboratory for the scintigraphic detection of melanoma and metastases. Optimal time for imaging was between 18-24 h p.i.